Kaletra (lopinavir/ritonavir)

DRUG5 trials

Sponsors

ViiV Healthcare, Abbott, ANRS, Emerging Infectious Diseases, Yale University, University of Cincinnati

Conditions

HIV InfectionHIV InfectionsHepatitis CInfection, Human Immunodeficiency Virus I

Phase 2

GW873140 In Combination With Kaletra In HIV Infected Subjects

TerminatedNCT00102778

ViiV HealthcareHIV Infection, Infection, Human Immunodeficiency Virus I

Start: 2004-12-31End: 2007-09-30Target: 175Updated: 2017-05-30

A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects

WithdrawnNCT00121017

AbbottHepatitis C, HIV Infection

Target: 200Updated: 2006-07-27

Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva

CompletedNCT00424814

ANRS, Emerging Infectious DiseasesHIV Infections

Start: 2007-03-31End: 2012-11-30Updated: 2013-07-18

Phase 4

Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection

CompletedNCT00885664

University of CincinnatiHIV Infections

Start: 2005-10-31End: 2010-03-31Updated: 2022-08-10

Unknown Phase

Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)

CompletedNCT00571961

Yale UniversityHIV Infections

Start: 2007-01-31End: 2008-08-31Updated: 2012-11-21

Related Papers

In Utero Exposure to Zidovudine and Heart Anomalies in the ANRS French Perinatal Cohort and the Nested PRIMEVA Randomized Trial

Clinical Infectious Diseases2015-04-0154 citations